TY - JOUR
T1 - Reclassifying the International Association for the Study of Lung Cancer Residual Tumor Classification According to the Extent of Nodal Dissection for NSCLC
T2 - One Size Does Not Fit All
AU - Lee, Junghee
AU - Hong, Yun Soo
AU - Cho, Juhee
AU - Lee, Jin
AU - Lee, Genehee
AU - Kang, Danbee
AU - Yun, Jeonghee
AU - Jeon, Yeong Jeong
AU - Shin, Sumin
AU - Cho, Jong Ho
AU - Choi, Yong Soo
AU - Kim, Jhingook
AU - Zo, Jae Ill
AU - Shim, Young Mog
AU - Guallar, Eliseo
AU - Kim, Hong Kwan
N1 - Publisher Copyright:
© 2022 International Association for the Study of Lung Cancer
PY - 2022/7
Y1 - 2022/7
N2 - Introduction: The extent of nodal assessment may require risk-based adjustments in NSCLC. We reclassified the International Association for the Study of Lung Cancer Residual tumor classification according to the extent of nodal dissection and evaluated its long-term prognosis by tumor stage and histologic subtype. Methods: We reclassified 5117 patients who underwent resection for clinical stages I to III NSCLC and had complete or uncertain resection by International Association for the Study of Lung Cancer classification into the following 3 groups according to compliance with three components (N1, N2, and subcarinal node) of systematic nodal dissection criteria: fully compliant group (FCG), partially compliant group (PCG), and noncompliant group (NCG). Recurrence-free survival (RFS) and overall survival (OS) were compared. Results: Of the 5117 patients, 2806 (55%), 1959 (38%), and 359 (7%) were FCG, PCG, and NCG, respectively. PCG and NCG were more likely to be of lower clinical stage and adenocarcinoma with lepidic component than FCG. The 5-year RFS and OS were significantly better in NCG than in FCG or PCG (RFS, 86% versus 70% or 74%, p < 0.001; OS, 90% versus 80% or 83%, p < 0.001). In particular, NCG had better RFS and OS than FCG or PCG in clinical stage I and in lepidic-type adenocarcinoma. Conclusions: In early stage NSCLC with low-risk histologic subtype, a less rigorous nodal assessment was not associated with a worse prognosis. Although surgeons should continue to aim for complete resection and thorough nodal assessment, a uniform approach to the extent and invasiveness of nodal assessment may need to be reconsidered.
AB - Introduction: The extent of nodal assessment may require risk-based adjustments in NSCLC. We reclassified the International Association for the Study of Lung Cancer Residual tumor classification according to the extent of nodal dissection and evaluated its long-term prognosis by tumor stage and histologic subtype. Methods: We reclassified 5117 patients who underwent resection for clinical stages I to III NSCLC and had complete or uncertain resection by International Association for the Study of Lung Cancer classification into the following 3 groups according to compliance with three components (N1, N2, and subcarinal node) of systematic nodal dissection criteria: fully compliant group (FCG), partially compliant group (PCG), and noncompliant group (NCG). Recurrence-free survival (RFS) and overall survival (OS) were compared. Results: Of the 5117 patients, 2806 (55%), 1959 (38%), and 359 (7%) were FCG, PCG, and NCG, respectively. PCG and NCG were more likely to be of lower clinical stage and adenocarcinoma with lepidic component than FCG. The 5-year RFS and OS were significantly better in NCG than in FCG or PCG (RFS, 86% versus 70% or 74%, p < 0.001; OS, 90% versus 80% or 83%, p < 0.001). In particular, NCG had better RFS and OS than FCG or PCG in clinical stage I and in lepidic-type adenocarcinoma. Conclusions: In early stage NSCLC with low-risk histologic subtype, a less rigorous nodal assessment was not associated with a worse prognosis. Although surgeons should continue to aim for complete resection and thorough nodal assessment, a uniform approach to the extent and invasiveness of nodal assessment may need to be reconsidered.
KW - Inadequate nodal assessment
KW - Non–small cell lung cancer
KW - Residual tumor
KW - Systematic nodal dissection
KW - Uncertain resection
UR - http://www.scopus.com/inward/record.url?scp=85130378974&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2022.03.015
DO - 10.1016/j.jtho.2022.03.015
M3 - Article
C2 - 35462086
AN - SCOPUS:85130378974
SN - 1556-0864
VL - 17
SP - 890
EP - 899
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 7
ER -